GME
GameStop Corp.
GME offers stronger valuation, but that advantage does not outweigh its weaker overall profile.
XPEV
XPeng Inc.
XPEV has the edge over GME overall, supported by stronger modeled upside and lower modeled downside.
GME Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Strong | |
| Strong | |
| Unavailable |
GME's profitability and cash flow are currently strong, and its revenue is stable. There isn't enough data to rate its balance sheet.
XPEV Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Under pressure | |
| Stable | |
| Unavailable |
XPEV's revenue and cash flow are currently stable, but its profitability is under pressure. There isn't enough data to rate its balance sheet.
GME PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 17x | $25.62 | — |
| Cheap | 18x | $27.96 | +9.1% |
| Forward | 38x | $25.62 | — |
| Fair | 43x | $66.84 | +161% |
| Expensive | 252x | $388 | +1414% |
Historical ranges are pointers, not guarantees.
GME's PE is in its cheap range at 17x. Analysts expect earnings to fall, which would put today's price at 38x next year's earnings, in its fair range.
XPEV PE Valuation
XPEV has no meaningful PE right now: it lost money over the past year.
GME Forward outlook
| Metric | Outlook |
|---|---|
| Strongly deteriorating | |
| Strong decline | |
| Strong decline | |
| Strongly weakening | |
| Limited | |
| High |
Analysts expect GME's earnings and revenue to decline, with profitability weakening.
XPEV Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| Improving | |
| Limited | |
| Low |
XPEV has the edge over GME on the outlook, with more favorable earnings and revenue expectations.
GME Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.67 | -56% |
| Q3 2026 | $1.54 | +93% |
| Q2 2026 | $1.34 | +153% |
| Q1 2026 | $0.77 | +133% |
| Q4 2025 | $0.89 | +394% |
| Q3 2025 | $0.80 | +515% |
| Q2 2025 | $0.53 | +563% |
| Q1 2025 | $0.33 | +1550% |
| Q4 2024 | $0.18 | +$0.21 |
GME has the edge over XPEV on earnings quality, reporting a profit while its opponent remains loss making.
XPEV Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$0.93 | -$0.25 |
| Q1 2026 | -$0.58 | +$0.23 |
| Q4 2025 | -$0.12 | +$0.80 |
| Q3 2025 | -$0.45 | +$0.47 |
| Q2 2025 | -$0.68 | +$0.63 |
| Q1 2025 | -$0.81 | +$0.79 |
| Q4 2024 | -$0.92 | +$0.87 |
| Q3 2024 | -$0.92 | +$1.07 |
XPEV is still losing money, but far less than before: $0.93 per share over the past year, against $1.99 at its worst in late 2023.
GME Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $790.2M | -19% |
| Q2 2026 | $835.3M | +14% |
| Q1 2026 | $1.1B | -14% |
| Q4 2025 | $821M | -4.6% |
| Q3 2025 | $972.2M | +22% |
| Q2 2025 | $732.4M | -17% |
| Q1 2025 | $1.3B | -28% |
| Q4 2024 | $860.3M | -20% |
GME's revenue has slid since its 2022 peak: $790M last quarter, down 19% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 20% | +13 points |
| Q2 2026 | 17% | +19 points |
| Q1 2026 | 12% | +6 points |
| Q4 2025 | 5% | +8.9 points |
| Q3 2025 | 6.8% | +9.6 points |
| Q2 2025 | -1.5% | +4.3 points |
| Q1 2025 | 6.2% | +3.1 points |
| Q4 2024 | -3.9% | -2.5 points |
GME has the edge over XPEV on profitability, with a higher operating margin.
XPEV Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $3B | +7.7% |
| Q1 2026 | $1.9B | -18% |
| Q4 2025 | $3.3B | +36% |
| Q3 2025 | $3.1B | +102% |
| Q2 2025 | $2.7B | +125% |
| Q1 2025 | $2.4B | +141% |
| Q4 2024 | $2.4B | +23% |
| Q3 2024 | $1.5B | +18% |
XPEV has the edge over GME on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -6.7% | -1.6 points |
| Q1 2026 | -16% | -9.6 points |
| Q4 2025 | -4.2% | +5.5 points |
| Q3 2025 | -3.7% | +15 points |
| Q2 2025 | -5.1% | +15 points |
| Q1 2025 | -6.6% | +19 points |
| Q4 2024 | -9.7% | +6.1 points |
| Q3 2024 | -18% | +19 points |
XPEV's operating margin was −6.7% last quarter, down 1.6 points from the same quarter a year ago.
GME Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $60.7M | -46% |
| Q2 2026 | $332.9M | +76% |
| Q1 2026 | $187.4M | +18% |
| Q4 2025 | $107M | +435% |
| Q3 2025 | $113.3M | +73% |
| Q2 2025 | $189.6M | +$304.3M |
| Q1 2025 | $158.8M | +$177.5M |
| Q4 2024 | $20M | +80% |
GME has the edge over XPEV on cash flow, with more consistent year-over-year improvement.
XPEV Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $0 | $0 |
| Q1 2026 | $0 | $0 |
| Q4 2025 | $0 | $0 |
| Q3 2025 | $0 | $0 |
| Q2 2025 | $0 | $0 |
| Q1 2025 | $0 | $0 |
| Q4 2024 | $0 | $0 |
| Q3 2024 | $0 | $0 |
XPEV's free cash flow was $0 over the past year, against $0 the year before.
GME Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.1% | +300K shares |
| 1 year | +8.4% | +46.1M shares |
| 3 years | +94% | +288M shares |
| 5 years | +104% | +302M shares |
| Available history | +80% | +264M shares |
GME has 593M diluted shares, up 8.4% from a year ago.
| Quarter | Spent |
|---|---|
| Q1 2021 | — |
| Q4 2020 | — |
| Q1 2020 | $21.8M |
| Q4 2019 | $114M |
XPEV Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.1% | +541K shares |
| 1 year | -49% | -467M shares |
| 3 years | -45% | -383M shares |
| 5 years | -44% | -377M shares |
| Available history | -44% | -377M shares |
XPEV has the edge over GME on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | — |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
XPEV hasn't bought back shares in the past year.
GME Net Leverage
XPEV Net Leverage
XPEV's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
GME Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 59.9 | Neutral |
| Stochastic | 68.5 | Neutral |
GME's weekly RSI is 60 (neutral) and its Stochastic is 69 (neutral).
XPEV Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 35.5 | Neutral |
| Stochastic | 17.7 | Oversold |
XPEV's weekly RSI is 36 (neutral) and its Stochastic is 18 (oversold).
GME PE vs Consumer Cyclical Sector
| Metric | GME | Sector median | Relative |
|---|---|---|---|
| PE | 17x | 18x | 7.7% below |
| PE % | 15 | 47 | 32 pts below |
GME is trading at 17x earnings, in line with the Consumer Cyclical sector's median of 18x.
XPEV PE vs Consumer Cyclical Sector
XPEV has no meaningful PE right now: it lost money over the past year.
GME Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $25.2 | 1.8% above |
| 20 week MA | $22.4 | 15% above |
| 50 week MA | $22.6 | 13% above |
| 100 week MA | $24.0 | 7% above |
| 200 week MA | $21.8 | 17% above |
GME has the edge over XPEV on trend strength, trading above more of its moving averages.
XPEV Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $9.56 | 1% below |
| 20 week MA | $11.1 | 14% below |
| 50 week MA | $14.9 | 37% below |
| 100 week MA | $17.2 | 45% below |
| 200 week MA | $14.2 | 33% below |
XPEV is in a downtrend: it's below all five of its weekly moving averages, and 33% below its 200-week average.
GME Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $1.48 | $5.04 | +241% |
| 2021 | $5.04 | $38.0 | +655% |
| 2022 | $38.0 | $20.1 | -47% |
| 2023 | $20.1 | $17.5 | -13% |
| 2024 | $17.5 | $32.2 | +84% |
| 2025 | $32.2 | $21.1 | -35% |
| 2026 YTD | $21.1 | $25.6 | +21% |
GME has the edge over XPEV on returns for 2026, with the stronger performance.
XPEV Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $22.8 | $41.9 | +84% |
| 2021 | $41.9 | $46.1 | +10% |
| 2022 | $46.1 | $10.1 | -78% |
| 2023 | $10.1 | $14.6 | +45% |
| 2024 | $14.6 | $12.6 | -13% |
| 2025 | $12.6 | $20.8 | +65% |
| 2026 YTD | $20.8 | $9.46 | -54% |
XPEV is down 54% so far in 2026, after finishing higher in four of the previous six years.